The pharmaco-economics of atypical antipsychotics

International Journal of Psychiatry in Clinical Practice

Volumn 3, Issue 4, 1999, Pages 237-248

  Taylor, David ^a,b   Aitchison, Katherine J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Amisulpride; Atypical antipsychotics; Cost effectiveness; Pharmaco economics

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTINDOLE;

COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH ECONOMICS; PRIORITY JOURNAL; PSYCHOSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; TREATMENT OUTCOME;

EID: 0033382490     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.3109/13651509909068390     Document Type: Review

References (52)

1. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-96.
2. Carman J, Peuskens J, Vangeneugden A (1993) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 10: 207-13.
3. Dunn CJ, Fitton A (1996) Sertindole. CNS Drugs 5: 224-30.
4. Tollefson GD, Beasley CM., Tran PV et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154; 457-65.
5. Boyer P, Lecrubier Y, Puech AJ et al (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: 68-72.
6. Lieberman JA (1996) Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rational hypothesis. J Clin Psychiatry 57 (Suppl 11): 68-71.
7. Knapp MRJ (1996) Cost-effectiveness in the treatment of schizophrenia. Eur Psychiatry 11: 137-43.
8. Walley T, Haycox A (1997) Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol 43: 343-8.
9. Drummond MF, Stoddart GL, Torrance GW (1987) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford.
10. Robinson R (1993) Economic evaluation and health care: what does it mean? Br Med J 307: 670-3.
11. Davies LM, Drummond MF (1994) Economics and schizophrenia: the real cost. Br J Psychiatry 165 (suppl 25): 18-21.
12. Revicki DA, Luce BR, Weschler JM (1990) Cost-effectiveness of dozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 41: 850-4.
13. Frank RG (1991) Clozapine's cost benefits [Letter]. Hosp Community Psychiatry 42: 92.
14. Goldman HH (1991) Clozapine's cost benefits [Letter]. Hosp Community Psychiatry 42: 92-3.
15. Revicki DA, Luce BR, Weschler JM et al (1991) Clozapine's cost benefits [Letter]. Hosp Community Psychiatry 42: 93-4.
16. Honigfeld G, Patin J (1990) A two-year clinical and economic follow-up of patients on dozapine. Hosp Community Psychiatry 41: 882-5.
17. Frankenburg FR, Zanarini MC, Cole JO et al (1992) Hospitalisation rates among clozapine-treated patients: a prospective cost-benefit analysis. Ann Clin Psychiatry 4: 247-50.
18. Meltzer HY, Cola P, Way L et al (1993) Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 150: 1630-8.
19. Schiller M, Hargreaves WA (1995) Clozapine's cost effectiveness [Letter]. Am J Psychiatry 152: 151-2.
20. Essock SM (1995) Clozapine's cost effectiveness [Letter]. Am J Psychiatry 152: 152.
21. Meltzer HY, Cola P (1995) Dr Meltzer and Mr Cola reply [Letter]. Am J Psychiatry 152: 153-4.
22. Davies LM, Drummond MF (1993) Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 162: 38-42.
23. Matheson LA, Cook HM, McKenna P et al (1994) Value for money care for patients with schizophrenia. Br J Med Economics 7: 25-34.
24. Shepherd M, Watt D, Falloon I et al (1989) The natural history of schizophrenia; a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychiatr Med 15: 1-46.
25. Reid WH, Mason M, Toprac M (1994) Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 45: 261-4.
26. Jonsson D, Wålinder J (1995) Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 92: 199-201.
27. Essock SM (1996) Clozapine eligibility among State hospital patients. Schizophr Bull 22: 15-25.
28. Aitchison KJ, Kerwin RW (1997) Cost-effectiveness of clozapine: a UK clinic-based study. Br J Psychiatry 171: 125-30.
29. Robert G, Kennedy P (1997) Establishing cost-effectiveness of atypical neuroleptics. Br J Psychiatry 171: 103-4.
30. Rosenheck R, Cramer J, Xu W et al (1997) A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 337: 809-15.
31. Geronimi-Ferret D, Lesay M, Barges-Bertocchio MH et al (1997) Evaluation médico-économique du traitement par la clozapine versus les traitements neuroleptiques antérieurs. L'Encéphale Sp IV: 24-31.
32. Reid WH, Mason M (1998) Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a State mental health care system. J Clin Psychiatry 59: 189-94.
33. Laker MK, Duffett RS, Cookson JC (1998) Long-term outcome with clozapine: comparison of patients continuing and discontinuing treatment Int Clin Psychopharmacol 13: 75-8.
34. Pollack S, Woerner MG, Howard A et al (1998) Clozapine reduces rehospitalizaion among schizophrenia patients. Psychopharmacol Bull 34: 89-92.
35. Addington DE, Jones B, Bloom D et al (1993) Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 15: 917-26.
36. Guest JF, Hart WM, Cookson RF et al (1996) Pharmaco-economic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Economics 10: 59-67.
37. Albright PS, Livingstone S, Keegan DL et al (1996) Reduction of Healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clin Drug Invest 11: 289-99.
38. Chouinard G, Albright PS (1997) Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 17: 298-307.
39. Viale G, Mechling L, Maislin G et al (1997) Impact of risperidone on the use of mental health care resources. Psychiatric Services 48: 1153-9.
40. Finley PR, Sommer BR, Corbitt JL et al (1998) Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 34: 75-81.
41. Ginsberg G, Shani S, Lev B (1998) Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel. Pharmacoeconomics 13: 231-41.
42. Ereshefcky L, Nabulsi A, Silber C et al (1997) Reduction of hospital days in sertindole treated patients: one year findings. Schirophr Res 24: 201-2.
43. Glazer WM, Johnstone BM (1997) Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 58 (suppl 10): 50-4.
44. Sacristán JA, Gómez JC, Martin J et al (1998) Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study. Clin Drug Investigation 15: 29-35.
45. Palmer CS, Revicki DA, Genduso LA et al (1998) A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Managed Care 4: 345-55.
46. Beasley CM, Tollefson G, Tran P et al (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind trial. Neuropsychopharmacology 14: 111-23.
47. Almond S, O'Donnell O (1998) Cost analysis of the-treatment of schizophrenia in the UK: A comparison of olanzapine and haloperidol. Pharmacoeconomics 13: 575-88.
48. Souêtre E, Martin P, Lecanu JP et al (1992) Évaluation médico-économique des neuroleptiq́ues dans la schizophrénie: Amisulpride versus halopéridol. L'Encéphale, 18: 263-9.
49. Prakash A, Lamb HM (1998) Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 9: 153-75.
50. Byrom BD, Garratt CJ, Kilpatrick AT (1998) Influence of antipsychotic profile on cost of treatment of schizophrenia: a decision analysis approach. Int J Psych Clin Pract 2: 129-38.
51. Rosenheck R, Massari L, Frisman L (1993) Who should receive high-cost mental health treatment and for how long? Schizophr Bull 19: 843-52.
52. Umbricht DSG, Lieberman JA, Kane JM (1995) The clinical efficacy of clozapine in the treatment of schizophrenia. Rev Contemp Pharmacother 6: 165-86.